Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin.
Fiche publication
Date publication
janvier 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DONTENWILL Monique, Pr ENTZ-WERLE Natacha, Dr ETIENNE-SELLOUM Nelly, Dr MARTIN Sophie, Dr REITA Damien
Tous les auteurs :
Sani S, Pallaoro N, Messe M, Bernhard C, Etienne-Selloum N, Kessler H, Marinelli L, Entz-Werle N, Foppolo S, Martin S, Reita D, Dontenwill M
Lien Pubmed
Résumé
Despite extensive treatment, glioblastoma inevitably recurs, leading to an overall survival of around 16 months. Understanding why and how tumours resist to radio/chemotherapies is crucial to overcome this unmet oncological challenge. Primary and acquired resistance to Temozolomide (TMZ), the standard-of-care chemotherapeutic drug, have been the subjects of several studies. This work aimed to evaluate molecular and phenotypic changes occurring during and after TMZ treatment in a glioblastoma cell model, the U87MG. These initially TMZ-sensitive cells acquire long-lasting resistance even after removal of the drug. Transcriptomic analysis revealed that profound changes occurred between parental and resistant cells, particularly at the level of the integrin repertoire. Focusing on α5β1 integrin, which we proposed earlier as a glioblastoma therapeutic target, we demonstrated that its expression was decreased in the presence of TMZ but restored after removal of the drug. In this glioblastoma model of recurrence, α5β1 integrin plays an important role in the proliferation and migration of tumoral cells. We also demonstrated that reactivating p53 by MDM2 inhibitors concomitantly with the inhibition of this integrin in recurrent cells may overcome the TMZ resistance. Our results may explain some integrin-based targeted therapy failure as integrin expressions are highly switchable during the time of treatment. We also propose an alternative way to alter the viability of recurrent glioblastoma cells expressing a high level of α5β1 integrin.
Mots clés
glioblastoma, integrins, p53 reactivation, temozolomide resistance
Référence
Cancers (Basel). 2022 Jan 12;14(2):